Nanotech for Implantable Medical Devices and Drug Device
Combination Products. Develops drug eluting covered stents, as
well as high performance self-sealing peripheral vascular graft.
Overview
NICAST LTD. is a nanotech company, operating in the field of
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
biomaterials and possessing a broad spectrum of capabilities and
IP focused on the fabrication and use of nanometrics-scale
polymer matrices. NICAST's matrices mimic biological tissue and
therefore allow the creation of high performance biomimetic
implants. NICAST's proprietary technology is based upon
electrocapilary spinning of polymers, often referred to as
electrospinning.
NICAST currently uses electrospinning to create a proprietary
nanofiber-based drug eluting stent for treating coronary and
peripheral vascular disease. In the short-term, NICAST intends to
capitalize on its peripheral vascular access graft application
for end stage renal disease (ESRD) patients.
The Company's mission is to "Make Nanotech a Basic Component in
Implantable Medical Device Technology" and its strategy is to
"Implement Electrospining in Creating Superior Implantable
Devices for Cardiovascular Disorders".
Formation of nanometric-scale fibers is essentially based on one
method - electrocapilary spinning (in short - electrospinning) of
nano-fibers from polymer solutions and melts. It has been
reported in the literature that more than 30 different polymer
types including PA, PP, PE, PAN, PEO, PVA, PLA, aramids,
polyaniline, synthetic polypeptides, collagen, elastin,
fibrinogen, DNA and other biomaterials have been electrospun.
The application areas for nano-sized fibers include high
performance and multifunctional filters, smart surfaces of
medical textiles, scaffolds in tissue engineering, separators for
chemical sources of current, functional coatings on flexible and
hard substrates, building electronic circuits nano-composites
etc.
NICAST believes that there are four major factors differentiating
itself in the arena of electrospinning. These factors are (a) a
wide Intellectual Property portfolio (partly pending), (b) unique
know-how, (c) automated fabrication capabilities, and (d)
application development skills in the medical device field.
In spite of the fact that basic process of electrospinning has
been known since the 1930, the challenge of implementing to
commercial applications requiring high level of reproducibility
has probably not been met yet. To the best of NICAST's knowledge,
the only commercial field for electrospinning is in the
filtration industry, where the end-products' characteristics are
simple, well defined and measurable and do not impose too
stringent requirements over the microscopic features of the
nanofiber matrix.
